Treatment(s) now being considered-Immunotherapy - Page 2 of 4 Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Immunotherapy Posts on Medivizor

What factors can predict if melanoma patients respond to anti-PD-1 immunotherapy?

Posted by on Aug 2, 2018 in Melanoma | 0 comments

In a nutshell This study investigated whether there was a relationship between specific tumor characteristics (biomarkers) in melanoma patients and response to anti-PD-1 immunotherapy. This study found that patients with certain tumor characteristics had a better response to anti-PD-1 immunotherapy and experienced increased survival. Some background...

Read More

Treatment with vemurafenib plus cobimetinib does not affect health related quality of life in advanced melanoma patients

Posted by on Apr 1, 2018 in Melanoma | 0 comments

In a nutshell This study examined the side effects and health related quality of life (HRQL) of advanced melanoma patients treated with cobimetinib (Cotellic) plus vemurafenib (Zelboraf). Researchers suggested that these patients maintained their HRQL when compared with patients treated with vemurafenib alone. Some background Prior studies...

Read More

A review in melanoma brain metastasis treatment

Posted by on Nov 18, 2017 in Melanoma | 0 comments

In a nutshell This study reviewed the currently available treatments for melanoma brain metastasis (MBM; spread to the brain). Researchers reported that treatment should be personalized for the different types of patients.  Some background Melanoma has the highest risk of spreading to the brain among all common cancer types. Until the last...

Read More

Side effects of targeted therapies to treat metastatic colorectal cancer

Posted by on Nov 18, 2017 in Colorectal cancer | 0 comments

In a nutshell This study investigated the negative side effects of targeted therapy to treat elderly and younger metastatic (spread to other parts of the body) colorectal cancer patients. Researchers suggested that side effects were different between these patients. Some background Colorectal cancer is one of the most common cancers worldwide....

Read More

Nivolumab treatment is associated with an improved survival in advanced melanoma

Posted by on Oct 16, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the effect of nivolumab (Opdivo) in patients with progressive melanoma after ipilimumab (Yervoy) treatment. Researchers suggested that nivolumab treatment is associated with better response compared with chemotherapy. Some background Recent new therapies, such as immunotherapy, have changed the treatment of...

Read More

Treatment with PD-1 agents improves melanoma outcomes

Posted by on Oct 16, 2017 in Melanoma | 0 comments

In a nutshell This review investigated the effectiveness of PD-1 agents in the treatment of melanoma. Researchers suggested that treatment with these agents is associated with improved cancer outcomes.   Some background The best treatment for melanoma remains to be determined, however surgery may be associated with a high cure rate. Patients...

Read More

Looking for participants to test the safety and effectiveness of a vaccine combined with TLR agonists to treat melanoma

Posted by on Feb 19, 2017 in Melanoma | 0 comments

In a nutshell This phase 1/2 trial aims to test the safety and effectiveness of a combined treatment with the new vaccine LPV7 and TLR agonists in advanced melanoma patients after surgery. The main outcome to be measured will be the treatment toxicity and response of the tumors to the treatment. This trial is recruiting in Houston, Texas and...

Read More